Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
It is recommended that listeners log on 15 minutes early in order toregister and download any necessary software. For those unable to participateduring the live webcast, a recorded replay of the presentation will beavailable within 24 hours of the completion of the presentation through July26, 2008.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed toimproving the lives of people with cancer by changing the way cancer istreated(TM). The company, in collaboration with Bayer HealthCarePharmaceuticals, Inc., is developing and marketing Nexavar(R), a smallmolecule drug. Nexavar is currently approved for the treatment of livercancer and advanced kidney cancer. Additionally, Nexavar is beinginvestigated in several ongoing trials in non-small cell lung cancer,melanoma, breast cancer, and other cancers. For more information about Onyx,visit the company's website at http://www.onyx-pharm.com.
Nexavar(R) (sorafenib) tablets is a registered trademark of BayerPharmaceuticals Corporation.
SOURCE Onyx Pharmaceuticals, Inc.
You May Also Like